Overview

Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resistant major depressive disorder.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Quetiapine Fumarate
Serotonin
Serotonin Uptake Inhibitors